Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 dose-ranging study in essential hypertension
2007-001360-76Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sacubitril + valsartan, sacubitril and valsartan in essential hypertension (8 arms), sponsored by Novartis. Primary endpoints: Primary efficacy endpoint and Primary hypothesis comparison. Started Aug 2007; status: completed.
02
Drugs
sacubitril + valsartansacubitrilvalsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2007-001360-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001360-76.